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Phase I Trial of Intrapleural Docetaxel Administered
Through an Implantable Catheter in Subjects with a
Malignant Pleural Effusion
David R. Jones, MD,* Matthew D. Taylor, MD,* Gina R. Petroni, PhD,† Jianfen Shu, MS,†
Sandra G. Burks, BSN,* Thomas M. Daniel, MD,* and Heidi H. Gillenwater, MD‡
Introduction: Malignant pleural effusion (MPE) is a common
complication in patients with advanced malignancy. This dose escala-
tion phase I study was designed to determine the maximum tolerated
dose of intrapleural docetaxel administered through an implantable
catheter in subjects with MPE.
Methods: Subjects with MPE (n  15) with median age of 64.6
years and an Eastern Cooperative Oncology Group performance
status of 0 to 2 at baseline were enrolled into four single dose levels
of docetaxel administered intrapleurally after drainage of the pleural
effusion and insertion of an intrapleural catheter. The study deter-
mined the pharmacokinetic properties, clinical response, and toxic-
ity profile of intrapleural docetaxel.
Results: All patients tolerated the therapy well and there were no
significant toxicities. The majority of patients had a complete radio-
graphic response. All patients receiving dose 100 mg/m2 or higher
had a complete radiographic response. One dose-limiting toxicity
was encountered in the dose 50 mg/m2. Pharmacokinetic data
demonstrated peak plasma concentration of docetaxel between 30
minutes and 6 hours after infusion. Pleural exposure to docetaxel
was 1000 times higher than systemic exposure.
Conclusions: Single-dose intrapleural administration of doxetaxel is
well tolerated in patients with MPE with minimal toxicity. The
excellent clinical responses in this study after treatment with in-
trapleural doxetaxel suggest that further investigation is warranted.
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Malignant pleural effusion is a common and debilitatingcomplication associated with numerous types of ad-
vanced oncologic diseases. In the United States, there are
more than 150,000 new cases of malignant pleural effusions
(MPEs) each year. Two previous studies of MPEs demon-
strated the etiology to be lung cancer in 35 to 40% of patients
and breast cancer in 23 to 26% of patients.1–3 Of the patients
with MPEs, the majority are symptomatic with 96% present-
ing with dyspnea and 56% having complaints of pleuritic
chest pain.1
The prognosis of patients with MPE is poor, with the
average survival time after diagnosis being 3 to 6 months.1–3
Mortality is 54% at 1 month and 84% at 6 months.2,3 Survival
is slightly longer, averaging 9.6 months, in patients whose
malignant effusion is the initial manifestation of cancer.4
Patients with breast cancer and MPE commonly live for 1
year or more,5 whereas those with primary ovarian tumors
have an expected survival of 9 months.3 MPEs associated
with lung and gastric primary tumors have a shorter patient
survival.3
Traditional treatment of MPE consists of diagnostic
thoracentesis, tube thoracostomy, and intrapleural instillation
of a sclerosing agent to obliterate the pleural space and
prevent the reaccumulation of the effusion. Numerous scle-
rosing agents have been described in the literature including
chemicals such as talc,6 antineoplastics agents such as bleo-
mycin, doxorubicin, and mitomycin,7–9 biologic agents such
as interferon, interleukin-2, Staphylococcus superantigen,
Corynebacterium parvum, and Streptococcus pyogenes,10–17
and antibiotics such as tetracycline, doxycycline, and mino-
cycline.18–20 The success of preventing the reaccumulation of
the pleural effusion ranges between 40% and 100% for these
treatments.
Intrapleural chemotherapy for MPE has been suggested
to be useful in treating the underlying malignancy in addition
to providing local control of the effusion. Furthermore, the
intrapleural levels of a chemotherapy agent administered into
the pleural space can be significantly higher than the systemic
levels. A number of chemotherapy agents have been safely
administered intrapleurally (IPL) to patients with MPE, in-
cluding 5-fluorouracil, bleomycin, cisplatin, carboplatin, cyt-
arabine, etoposide, and paclitaxel. Reported pleural effusion
response rates at 3 to 4 weeks range from 46 to 100%,
depending on the agent.15,21–29
Because lung cancer accounts for approximately 50%
of all MPEs,5 we believe that docetaxel’s efficacy in the
treatment of locally advanced or metastatic non-small cell
lung cancer (NSCLC) may extend to the treatment of MPE as
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well. This phase I study was designed to determine the safety,
feasibility, and pharmacokinetics of single-dose intrapleural
administration of docetaxel for the treatment of MPEs.
PATIENTS AND METHODS
This study was a phase I, single institution, investiga-
tor-initiated trial. The trial was approved by the Institutional
Review Board for Health Sciences Research at the University
of Virginia and was conducted in accordance with the prin-
ciples of the Declaration of Helsinki. All patients signed
informed consent.
Patient Eligibility
Patients were included who met the following criteria:
age greater than 18; symptomatically, histologically, or cy-
tologically confirmed MPE; appropriate candidate for thora-
coscopic surgery; Eastern Cooperative Oncology Group per-
formance status of 2 or less; existing peripheral neuropathy
less than grade 1; absolute neutrophil count 1500/mm3,
hemoglobin 8.0 g/dl, platelet count 100,000/mm3; serum
creatinine 1.8 mg/dl; total bilirubin within normal limits,
transaminases (alanine aminotransferase and/or aspartate
transaminase) up to 1.5 institutional upper limit of normal
(ULN) if alkaline phosphatase is ULN or alkaline phospha-
tase up to 2.5 ULN if transaminases are ULN; interna-
tional normal ratio 1.5; and negative serum or urine preg-
nancy test for women of childbearing age. Exclusion criteria
included prior ipsilateral pleurodesis, bilateral MPE, and a
history of hypersensitivity reaction to docetaxel or other drugs
formulated with polysorbate 80.
Study Design
The primary objective of the trial was to determine the
maximum tolerated dose (MTD) of intrapleural docetaxel in
subjects with MPE. Patients were enrolled into one of four
dose cohorts (50, 75, 100, or 125 mg/m2) of three to six
patients. If one of the first three patients in any cohort
experience dose-limiting toxicity (DLT), the cohort was ex-
panded to six patients. If at any time two or more patients in
a cohort experienced DLT, the MTD was exceeded, and the
next lowest cohort was the MTD. DLT was defined as any
grade 4 investigational intrapleural chemotherapy related he-
matologic toxicity lasting 7 days, any grade 4 investiga-
tional intrapleural chemotherapy related neutropenic fever, or
any grade 3 or higher investigational intrapleural chemother-
apy related nonhematologic toxicity. The starting dose of 50
mg/m2 docetaxel was 0.66 times the recommended intrave-
nous (IV) dose for the systemic treatment of NSCLC, this
being 75 mg/m2 docetaxel.
Study Conduct
Before inclusion in the study, subjects provided written,
informed consent to participate in the study and underwent
standardized evaluations, including serum chemistries and a
chest radiograph. Baseline evaluations were conducted within
14 days before the date of surgery.
Subjects were admitted to the hospital on the same day
as their scheduled surgical procedure. Before the procedure, a
10 ml sample of blood was obtained through a previously
inserted intravenous or intraarterial line for pharmacokinetic
analysis. Subjects underwent thoracoscopic surgery for treat-
ment of their MPE according to the routine practice of this
institution. Using a minimally invasive approach, intrapleural
adhesions were lysed, and all fluid was evacuated and sam-
pled for baseline pharmacokinetic studies. At the completion
of the procedure, a small-bore closed tube thoracostomy was
inserted and connected to 20 cm H2O suction utilizing a
pleurovac apparatus. A second soft, silicone 15.5-F intrapleural
catheter (Pleurx, Denver Biomedical, Golden, CO) was inserted
through a separate site and secured. The smaller, soft Pleurx
catheter was subsequently used to instill the docetaxel later in
the protocol. Within 4 hours postprocedure, the subjects were
examined, the chest tube evaluated for evidence of an air leak,
and the chest roentgenogram (CXR) examined.
Subjects were premedicated with dexamethasone 8 mg
PO twice a day for 3 days, starting on the day of surgery,
diphenhydramine 50 mg PO or IV, and famotidine 20 mg IV
or PO 1 hour before docetaxel administration.
When the drainage from the chest tube was 300 ml/
24 h and there was no air leak, and the CXR demonstrated no
pneumothorax or significant effusion, docetaxel (mixed in
100 ml normal saline) was IPL injected through the Pleurx
catheter over 3 minutes. The chest tube and Pleurx catheter
were both clamped for 4 hours after this infusion. The
subjects were placed in several different positions to facilitate
uniform distribution of the docetaxel. Peripheral blood and
pleural fluid were obtained for subsequent pharmacokinetic
analysis. The chest tube and Pleurx catheter were unclamped
after the 4 hour “dwell time,” and the chest tube returned to
suction. When the chest tube drainage was300 ml/24 h, the
chest tube and catheter were removed. A peripheral blood
sample was obtained to evaluate blood chemistry, liver func-
tion, and complete blood count. Subjects were discharged
when medically stable.
Posttreatment Monitoring
All subjects were seen between day 5 and day 9
postdrug administration to evaluate for adverse events. Fol-
low-up of subjects was continued 3 weeks after the first
docetaxel administration and included a CXR and routine
laboratories. The CXR was compared with one obtained at
baseline, and pleural effusion response was measured. Ad-
verse events were recorded and graded according to the
National Cancer Institute Common Toxicity Criteria version
2.0. Subjects were followed for life and time to MPE pro-
gression and survival were documented.
Measurement of Clinical Response
A chest radiograph obtained 3 weeks postdocetaxel
instillation was compared with one obtained presurgery to
estimate MPE response using set criteria to define complete
response, partial response, stabilization, and progression. The
response criteria used was based on a previous study by the
Lung Cancer Study Group in a trial of intrapleural cisplatin
and cytarabine in patients with MPE.30 The response criteria
was as follows: (1) Complete response: total disappearance of
pleural fluid or residual pleural fluid too minimal to be
approachable by thoracentesis; (2) Partial response: 75% or
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greater reduction of pleural effusion compared with baseline
pretreatment chest radiograph; (3) Stabilization: less than a
75% reduction and not greater than 25% increase in the
amount of pleural fluid compared with baseline chest radio-
graph; and (4) Progression: greater than 25% increase of
pleural fluid compared with baseline chest radiograph.
Pharmacokinetics Analysis
The pharmacokinetics of docetaxel was assessed in
plasma and pleural fluid. Peripheral blood and pleural fluid
samples were collected for pharmacokinetic analysis before
docetaxel administration at the time of surgery (baseline) and
at the following time points: 30 minutes, 1 hours, 6 hours, 24
hours, and 36 hours postdocetaxel instillation. Pharmacokinetic
parameters were estimated using standard methodology.31
RESULTS
Patient Demographics
From November 2003 to February 2006, 15 patients
were enrolled in the study. Table 1 illustrates the patient
characteristics. Radiographically all pleural effusions were
estimated to have 500 to 750 ml of intrapleural fluid at a
minimum with several containing 2000 ml or more. There
were nine men and six women enrolled in the study with a
median age of 65 years (range, 43–82 years). Over 50% of
the patients in the study had MPE due to NSCLC.
All patients had been treated with either chemotherapy
or radiotherapy, although 53% (8 of 15) had had no treatment
within the 2 months before enrollment in the study. As noted
previously, prior treatment with docetaxel was not an exclu-
sion criteria for the study, and as such 7 of 15 (47%) patients
had docetaxel or other paclitaxel before enrolling in the
study. Eighty percent (12 of 15) of patients received chemo-
therapy and/or radiation after completion of their intrapleural
chemotherapy. Of these, two patients had paclitaxel after com-
pletion of the clinical trial. There was no correlation between
pretrial or posttrial administration of systemic taxanes and re-
sponse to intrapleural docetaxel as part of the trial. In addition,
there were no delays to initiation of the posttrial chemotherapy
secondary to participation in this clinical trial.
Toxicity
There were six patients in cohort 1 (50 mg/m2) and
three in each of the remaining cohorts (75, 100, and 125
mg/m2). There was one DLT in the 50 mg/m2 dosing level,
which was a grade 3 infection without neutropenia. This
infection was believed to be related to the presence of the
intrapleural catheter used for instilling the docetaxel, which
remained in place after hospital discharge. The protocol was
modified to require removal of the intrapleural catheter before
hospital discharge, and no further infections of this nature
were observed. A second cohort of three subjects treated at
the 50 mg/m2 dose experienced no DLTs.
Table 2 demonstrates the number of adverse events per
dose level and the severity of the adverse events. Adverse
events were similar across all dose levels. Adverse events
judged unrelated to the intrapleural chemotherapy were not
considered DLTs regardless of their severity. All adverse
events were monitored by the Data Safety Monitoring Com-
mittee for the Cancer Center at the University of Virginia.
Clinical Response
After intrapleural administration of docetaxel, all pa-
tients received serial chest radiographs at 3 weeks to evaluate
for the recurrence of the MPE. The clinical response for each
dose level of docetaxel is shown in Table 3. Of the patients
receiving 75 mg/m2 or higher doses of docetaxel, 90% dem-
onstrated a complete response with no evidence of residual
pleural effusion. All patients receiving 100 mg/m2 or more of
docetaxel had a complete response to therapy. Six patients
had evidence of recurrent effusion; however, only two pa-
tients required reintervention (one Pleurx catheter insertion
and one thoracentesis) for symptomatic relief.
All patients died in the follow-up period. Median survival
time was 3.6 months (range, 1.5–17.9 months). Median survival
for patients receiving 50mg/m2 was 4.0 months (range, 1.5–17.9
months), 75 mg/m2 was 2.7 months (range, 2.1–9.6 months),
100 mg/m2 was 8.5 months (range, 7.9–16.5 months), and 125
mg/m2 was 3.1 months (range, 1.7–7.1 months).
Pharmacokinetic Analysis
Pleural fluid and plasma samples were obtained from all
patients and pharmacokinetic parameters with elimination
curves are displayed in Figures 1 and 2, respectively. Peak
intrapleural docetaxel concentrations were achieved at approxi-
mately 60 minutes after infusion. We did note that there was a
slight resurgence in intrapleural docetaxel concentrations about
24 hours postinstillation. This is thought to be secondary to
mobilization of the patient with more “pockets” of docetaxel
instillate being evacuated by the chest tube and then measured.
Peak intrapleural docetaxel concentrations ranged from
1000 to 1600 mol/l. The half-life elimination of docetaxel
from the pleural space ranged from 4.1 to 5.7 hours with no
TABLE 1. Demographic and Baseline Characteristics
Characteristic No. %
Age (yr)
Median (range) 65 (43–83)
Gender
Male 9 60
Female 6 40
Race
White 13 87
African American 2 13
ECOG performance status
0 3 20
1 6 40
2 6 40
Primary malignancy
NSCLC 8 53.3
Breast cancer 4 26.6
Ovarian cancer 1 6.7
Oral cancer 1 6.7
Mesothelioma 1 6.7
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer.
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appreciable correlation with dose level. Pleural exposure to
docetaxel as expressed by the area under the curve (AUC)
ranged from 4356 to 12,617 (mol/l)h and inversely corre-
lated with increasing dose levels.
Peak plasma docetaxel levels were discovered from
approximately 0.5 to 6 hours after intrapleural infusion with
concentrations ranging from 0.17 to 0.48 mol/l and without
correlation to the dose level. When comparing pleural expo-
TABLE 2. Adverse Events of Intrapleural Docetaxel
Intrapleural Docetaxel Dose Levels
Toxicity
50 mg/m2 (N  6) 75 mg/m2 (N  3) 100 mg/m2 (N  3) 125 mg/m2 (N  3)
Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
Hematologic
Anemia 1 — 1 — — — — —
Neutropenia — — — — — — — —
Thrombocytopenia — — — — — — — —
Cardiovascular
Tachycardia 2 — — — — — — —
Hypotension 1 — — — — — — —
Pulmonary embolism — 1 — — — — — —
Pulmonary
Cough 1 — — — — — 1 —
Recurrent effusion 1 — 1 1 1 — — —
Pneumothorax — — 2 — — — — —
Hypoxia — — — — — — 1 1
Dyspnea — — — — — — — 1
Pneumonia — — — 1 — — — —
Renal
Elevated creatinine — — — — — — — 1
Metabolic
Hypocalcemia 1 — 2 — 1 — — —
Hypophosphatemia 1 — — — — — — —
Hyponatremia — — — — 2 — — —
Hypokalemia — — — — — — 1 —
Gastrointestinal
Vomiting 1 — 1 — — — — —
Stomatitis 1 — 1 — — — — —
Nausea — — 1 — 1 — — —
Dehydration — — 1 — — — — —
Hepatic
Elevated transaminases 5 — 2 — 2 — — —
Constitutional
Fever 3 — — — 1 — 2 —
Fatigue 3 — 1 — 2 — — —
Anorexia — — 1 — — — — —
Pain 6 1 1 1 — 3 1 —
Infection 1 2 — 1 — — 1 —
TABLE 3. Clinical Response to Intrapleural Docetaxel
Dose
(mg/m2)
Complete Response
Number This Response/
Total No. of Patients
at This Dose
Partial Response
Number This Response/
Total No. of Patients
at This Dose
Stabilized
Number This Response/
Total No. of Patients
at This Dose
50 1/6 3/6 2/6
75 2/3 1/3 0/3
100 3/3 0/3 0/3
125 3/3 0/3 0/3
All 9 4 2
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sure and plasma exposure to docetaxel by measuring AUCs,
pleural exposure to docetaxel was 1893 to 6675 times higher
than systemic exposure up to 36 hours postinfusion (Figure 1).
DISCUSSION
In patients with late-stage malignancies, the develop-
ment of a large MPE results in significant dyspnea, cough,
fatigue, and an inability to perform activities of daily living.
The goals of MPE treatment strategies are to palliate these
symptoms and to prevent recurrence of the MPE. Traditional
sclerosing agents such as talc, bleomycin, and tetracycline
derivatives have been used for the treatment of MPEs. Al-
though talc pleurodesis has been shown to be highly effective
in apposing lung parenchyma to the chest wall, its limitations
include severe pain from instillation and complications rang-
ing from acute pneumonitis, granulomatous pneumonitis, and
acute respiratory distress syndrome.32–34 Bleomycin’s success
as a sclerosing agent is associated with significant variability
ranging from 31 to 85%.35 Tetracycline derivatives have been
effective in treating MPEs; however, multiple instillations are
often necessary. The cost of using these sclerosing agents,
including talc pleurodesis, for treatment of MPEs in 1995 was
estimated to be between $8000 and $20,000 per treatment.35
Given the lack of large randomized prospective trials to
adequately differentiate the efficacy of various sclerosing
agents, no consensus has been reached regarding which agent
is best.
The administration of intracavitary chemotherapy for
MPE has become an attractive area of investigation as it may
be useful in treating the underlying malignancy in addition to
providing local control of the effusion. Indeed, intraperitoneal
levels 21-fold higher than serum levels have been reported
after the intraperitoneal administration of cisplatin. In theory,
such an approach could maximize the chemotherapeutic treat-
ment of local disease while minimizing systemic toxicity.
Limitations of this chemotherapeutic approach include the
need for good dispersal throughout the pleural cavity and
penetrance of only a few millimeters in patients with bulky
tumors.21
Many chemotherapeutic drugs have been administered
IPL including bleomycin, doxorubicin, cisplatin, etoposide,
fluorouracil, and mitomycin C.36 With the exception of bleo-
mycin, their main mechanism of action is due to their scle-
rosant effect on the pleura and not cytotoxicity.37 Despite
bleomycin’s known cytotoxic effect, it has poor antineoplas-
tic activity in most epithelial malignancies that result in MPE.
The taxane antimicrotubule agent paclitaxel has also
been safely administered IPL to patients with MPE. In a
phase I trial of 18 patients, the MTD of paclitaxel was found
to be 225 mg/m2, and dose-limiting toxicity involved the
development of severe dyspnea.25
Subsequently, a phase II trial of intrapleural paclitaxel
was then performed in 15 NSCLC patients with MPE caused
by NSCLC.38 Among the 14 patients evaluable at 4 weeks,
the effusion control rate was 92.9%. Similar to these results,
our study demonstrates a 90% effusion control rate at 3 weeks
with intrapleural docetaxel dose of 75 mg/m2 and 100%
effusion control with a dose of 100 mg/m2.
The pharmacological advantages of docetaxel over pac-
litaxel could be demonstrated by comparing the mean expo-
sure of drug to the pleural cavity (AUC) to that of the drug
exposure to plasma. As mentioned previously, paclitaxel had
FIGURE 1. Pleural pharmacokinetics parameters and me-
dian dose elimination curves following intrapleural docetaxel
dosing.
FIGURE 2. Plasma pharmacokinetics parameters and me-
dian dose elimination curves following intrapleural docetaxel
dosing.
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approximately a 370-fold higher exposure in the pleural
cavity compared with plasma, which represents at a minimum
a fivefold decrease in pleural exposure when compared with
docetaxel (1893–6675-fold pleural exposure). Nevertheless,
single-dose intrapleural serum clearance of docetaxel in this
study was significantly faster than the clearance of paclitaxel
with the majority of drug being cleared by 20 hours after
administration as compared with 48 to 96 hours with pacli-
taxel.38 Although speculative in nature, reasons why do-
cetaxel may be cleared more rapidly than paclitaxel include
different pharmacokinetics and differences in stability and
aqueous solubility between the two compounds.26,38
Interestingly, in our study, we observed that the AUC
for intrapleural docetaxel did not correlate with dose concen-
tration. This observation has been seen with other studies of
intrapleural chemotherapeutic agents including paclitaxel.38
This strongly suggest that intrapleural docetaxel may not
follow dose-dependent pharmacokinetics. Possible explana-
tions for this nonlinear pharmacokinetics could certainly
include saturability of docetaxel metabolism or alternatively
changes in the clearance of the drug secondary to nonlinear
drug binding to tissue proteins. Further investigation needs to
be performed to determine what effect this increased clear-
ance has on the cytotoxic capacity of docetaxel systemically.
The toxicity profile of intrapleural docetaxel is similar
to previous phase I/II trials using paclitaxel. Constitutional
symptoms were noted in 33% of patients in this study
compared with 26% in the paclitaxel study.38 The incidence
of anemia in this study and prior paclitaxel studies were the
same at 13%. No patients developed neutropenia from treat-
ment in this study compared with 6.7% with treatment of
paclitaxel. Interestingly, 60% of the patients in this study
receiving intrapleural docetaxel had modest and transient
elevation in hepatic transaminases with no clinical evidence
of hepatic insufficiency, as compared with 13% in the phase
II trial of paclitaxel.
Although efficacy was not a major end point in this
phase I trial, one cannot ignore that 90% of patients receiving
a single intrapleural dose of 75 mg/m2 or more had a com-
plete response to their pleural effusion at 3 weeks after
treatment. Previous work has suggested that the mechanism
of antimicrotubule chemotherapeutics in the pleural cavity is
due to the cytotoxic effect and less a result of the sclerosing
effect.25 This hypothesis is based on the absence of significant
intraabdominal adhesions at the time of exploratory laparot-
omy after intraperitoneal administration of paclitaxel.39 In
addition, previous investigation of intrapleural paclitaxel
found a 50% shrinkage in primary tumor in 1 patient of 14
patients, suggesting that intrapleural chemotherapy may have
some local systemic antitumor effect.38 Clearly, this phase I
study of docetaxel does not further elucidate the specific
mechanism of intrapleural docetaxel therapy. Further studies
appropriately powered to assess docetaxel’s efficacy after
intrapleural administration are necessary. In addition, future
investigation should be aimed at assessing systemic antitumor
activity of docetaxel by measuring the change in size of the
primary tumor after intrapleural therapy.
In conclusion, single-dose intrapleural docetaxel for MPEs
was feasible at doses of 50 to 125 mg/m2 in this phase I clinical
trial. Further clinical investigation of intrapleural docetaxel is
warranted to determine efficacy for treatment of MPEs.
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